Renalytix (LSE:RENX) ROCE % : -2,747.65% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Renalytix ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Renalytix's annualized ROCE % for the quarter that ended in Mar. 2024 was -2,747.65%.

Renalytix ROCE % Historical Data

The historical data trend for Renalytix's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix ROCE % Chart

Renalytix Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-1,049.15

-44.50

-51.94

-87.20

-157.10

Renalytix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-210.81	-195.63	-382.89	-577.80	-2,747.65

Renalytix ROCE % Calculation

Renalytix's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-33.439	/	( ( (40.653 - 9.562)	+	(24.258 - 12.78) )	/ 2 )
	=	-33.439	/	( (31.091	+	11.478)	/ 2 )
	=	-33.439	/	21.2845
	=	-157.10 %

Renalytix's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-19.316	/	( ( (17.28 - 10.979)	+	(6.901 - 11.796) )	/ 2 )
	=	-19.316	/	( ( 6.301	+	-4.895 )	/ 2 )
	=	-19.316	/	0.703
	=	-2,747.65 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Renalytix (LSE:RENX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Renalytix ROCE % Related Terms

Thank you for viewing the detailed overview of Renalytix's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Renalytix (LSE:RENX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (LSE:RENX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RNLX:USA RTNXF:USA 2O9:Germany

Address

5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE

Website

https://www.renalytix.com

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Renalytix (LSE:RENX) Headlines

From GuruFocus

Omnicom Health Group acquires Elsevier's Pharma Communications business in Japan, rebrands as EMC K.K.

By PRNewswire PRNewswire • 03-27-2018

Causeway International's Top Five Holdings

By Monica Wolfe Monica Wolfe • 08-29-2013

Investing in Information

By Vanina Egea Vanina Egea • 03-06-2014

Paul Singer Buys Reed Elesvier

By matsandalex matsandalex • 12-14-2012